drug

milsaperidone

1 story · latest Aug 5, 2026

Status: FDA approved Feb 2026 · NDA220358
Brand: Bysanti

Relationships

Developed by Vanda Pharmaceuticals Inc.

Timeline

Vanda reports Q2 2026 results, reaffirms guidance and three Phase III readouts by year-end

Aug 5Quarterly updateiloperidone milsaperidone

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.